logo
Share SHARE
FONT-SIZE Plus   Neg

Sucampo, Abbott Say Sucampo Pharma, Ltd. Gets Approval For AMITIZA In Japan

Sucampo Pharmaceuticals, Inc. (SCMP) and Abbott (ABT) announced that Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, has received approval from the Ministry of Health, Labor and Welfare in Japan for AMITIZA (lubiprostone), a prescription medicine for the treatment of chronic constipation.

Sucampo submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market AMITIZA in September 2010. The application included data from a Phase 3 efficacy trial in 124 Japanese patients as well as from a long-term open-label safety trial in 209 Japanese patients who received lubiprostone for up to 48 weeks. The application also included data from previous trials conducted in the United States, Canada and Europe.

"We are very pleased to receive Japan's first-ever approval for a prescription medicine for chronic constipation as it helps us achieve our objective of bringing medicines with novel mechanisms of action to patients with unmet medical needs on a global basis," said Ryuji Ueno, Sucampo's Chairman and Chief Executive Officer. "We look forward to working with Abbott to meet the needs of these patients in Japan."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
TCL Communications CEO Nicolas Zibell announced the plan to launch new Blackberry brand smartphone with superior security features. The new android phone BlackBerry KeyOne will be a beginning of a new story, he noted. Though the iPhones with smarter and popular features killed the Canadian smartphone maker, the BlackBerry brand has been maintaining strong fan-following around the globe. Its secu In response to stiff competition from its rivals, AT&T Inc. has lowered the price of its unlimited data plan and is also offering a video credit if customers subscribe to a video service plan. The unlimited mobile data plan was made available to all AT&T customers less than two weeks ago. The plan for a single phone will now cost $90 for the first line, a price cut of $10. Discount-store operator Target, Inc. on Tuesday reported a 43 percent decline in profit in the fourth quarter from last year, reflecting lower sales and weaker margins. In addition, the prior-year period's results included a one-time gain. Adjusted earnings per share for the latest quarter missed analysts' expectations.
comments powered by Disqus
Follow RTT